At a glance
- Originator Abbott Laboratories
- Class Antineoplastics
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Cancer in USA (PO)
- 19 Apr 2002 Preclinical trials in Cancer in USA (PO)
- 19 Apr 2002 Profile was created from the 93rd annual meeting of the American Association for Cancer Research